Contacts

Dr. Gregor Schmid, LL.M. (Cambridge)

Partner

Read More

Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

Salary Partner

Read More

Dr. Jens Wolf

Partner

Read More

Philipp Hoegl

Salary Partner

Read More

Philipp Bergjans

Associate

Read More

Dr. Stefanie Greifeneder

Partner

Read More

Dr. Andrea Sautter

Salary Partner

Read More

Sherin Sayed

Associate

Read More

Nico Jänicke

Partner

Read More

Jan-Mathias Pfleging

Senior Associate

Read More

Thanos Rammos, LL.M.

Partner

Read More

Hazal Viola Koepp-Strand, LL.M. (Lund)

Associate

Read More

Dr. Eva Surowiecki, LL.B. (London)

Senior Associate

Read More
Contacts

Dr. Gregor Schmid, LL.M. (Cambridge)

Partner

Read More

Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

Salary Partner

Read More

Dr. Jens Wolf

Partner

Read More

Philipp Hoegl

Salary Partner

Read More

Philipp Bergjans

Associate

Read More

Dr. Stefanie Greifeneder

Partner

Read More

Dr. Andrea Sautter

Salary Partner

Read More

Sherin Sayed

Associate

Read More

Nico Jänicke

Partner

Read More

Jan-Mathias Pfleging

Senior Associate

Read More

Thanos Rammos, LL.M.

Partner

Read More

Hazal Viola Koepp-Strand, LL.M. (Lund)

Associate

Read More

Dr. Eva Surowiecki, LL.B. (London)

Senior Associate

Read More

27 February 2024

Bertelsmann Investments acquires pharma tech company EXTEDO with Taylor Wessing

Bertelsmann Investments acquires the pharmaceutical technology company EXTEDO for a double-digit million amount. A Taylor Wessing team led by the two partners Dr Gregor Schmid (Berlin) and Dr Niclas von Woedtke (Hamburg) advised Bertelsmann Investments on all legal issues in connection with the acquisition.

Bertelsmann Investments is the investment arm of Bertelsmann and has invested around €1.7 billion in over 400 innovative companies and funds to date. The venture capital company currently holds shares in more than 360 innovative companies and funds, particularly in the fields of education, digital media, fintech, e-commerce and adtech. The acquisition of EXTEDO expands Bertelsmann Investments' portfolio of companies with the aim of strategically expanding its position in the European growth market of pharma tech through synergies with existing portfolio companies. As a leading provider of software solutions and services in the field of regulatory information, EXTEDO brings extensive expertise to the table, which both industry customers and public authorities can draw on.

EXTEDO's customers include around 1,000 pharmaceutical companies and public institutions in more than 65 countries, including 35 regulatory authorities, which use the pharma tech service provider's solutions to optimise their regulatory business processes in the areas of document management, product registration, approval management and drug safety.

Legal advisors Bertelsmann Investments
Taylor Wessing Germany:
Jointly led by Dr Gregor Schmid (Partner, IP / IT / Data Law, Berlin) and Dr Niclas von Woedtke (Salary Partner, Corporate/M&A, Hamburg); Dr Jens Wolf (Partner), Philipp Hoegl (Salary Partner), Philipp Bergjans (Associate), all M&A/Venture Capital, all Hamburg; Dr Stefanie Greifeneder (Partner), Dr Andrea Sautter (Salary Partner), Sherin Sayed (Associate), all Patents Technology & Life Sciences, all Munich; Nico Jänicke (Partner), Jan-Mathias Pfleging (Senior Associate), Alois Lobkowicz (Associate), all Employment, Pensions & Mobility, all Berlin; Thanos Rammos (Partner), Hazal Viola Koepp-Strand (Associate), Dr. Eva Surowiecki, LL.B. (Associate), all IP/IT and Data Law, all Berlin

In-house Bertelsmann Investments: Dr Martin Dannhoff (lead)
Legal advisor to the seller: Dornbach RAe
 
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Corporate/M&A & capital markets

Healthcare & Life Sciences: Taylor Wessing advises Protembis GmbH on Series B financing round

27 March 2024

by multiple authors

Click here to find out more
Corporate/M&A & capital markets

Taylor Wessing advises Azenta Life Sciences on the acquisition of the Barkey Group

17 June 2022

by multiple authors

Click here to find out more
Corporate/M&A & capital markets

Taylor Wessing advises Formycon on acquisition of biosimilar assets in strategic partnership with ATHOS

31 March 2022

by multiple authors

Click here to find out more